subscribeSubscribe
Enforcement Report - Week of April 10, 2024

Enforcement Report - Week of April 10, 2024
FDA
10 Apr 2024
Share Share
Fresenius Kabi Further Expands Oncology Portfolio

Fresenius Kabi Further Expands Oncology Portfolio
BUSINESSWIRE
28 Feb 2024
Share Share
Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan

Panbela Announces Publication of Clinical Data Titled: Phase 1 study of high-dose DFMO, celecoxib, cyclophosphamide and topotecan
GLOBENEWSWIRE
18 Jan 2024
Share Share
RK Pharma`s Generic Cyclophosphamide Receives Approval in the U.S.

RK Pharma`s Generic Cyclophosphamide Receives Approval in the U.S.
FDA
18 Dec 2023
Share Share
Zydus Pharma`s Generic Cyclophosphamide Receives Approval in the U.S.

Zydus Pharma`s Generic Cyclophosphamide Receives Approval in the U.S.
FDA
13 Dec 2023
Share Share
Sagent`s Generic Cyclophosphamide Receives Approval in the U.S.

Sagent`s Generic Cyclophosphamide Receives Approval in the U.S.
FDA
17 Jul 2023
Share Share
Ibrutinib Plus Chemoimmunotherapy Fails to Improve PFS in Pretreated FL, MZL

Ibrutinib Plus Chemoimmunotherapy Fails to Improve PFS in Pretreated FL, MZL
Caroline Seymour ONCLIVE
20 Jun 2023
Share Share
FDA adcomm votes 11-2 to expand Roche`s Polivy label in DLBCL

FDA adcomm votes 11-2 to expand Roche`s Polivy label in DLBCL
Paul Schloesser ENDPTS
10 Mar 2023
Share Share
FDA Confirms Paragraph IV Patent Litigation for Cyclophosphamide Injection

FDA Confirms Paragraph IV Patent Litigation for Cyclophosphamide Injection
FDA
23 Feb 2023
Share Share
Stem cell transplants may slow disability progression in MS

Stem cell transplants may slow disability progression in MS
Caroline Peachey EUROPEANPHARMACEUTICALREVIEW
22 Dec 2022
Share Share